Harmony Biosciences Holdings Inc
Atidarymo kaina
SektoriusSveikatos priežiūra
33.6 -0.53
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
33.49
Max
34.54
Pajamos | 10M 32M |
|---|---|
Pardavimai | -28M 215M |
P/E Sektoriaus vid. | 12.984 49.052 |
Pelnas, tenkantis vienai akcijai | 0.786 |
Pelno marža | 15.084 |
Darbuotojai | 293 |
EBITDA | -2.8M 49M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +43.64% upside |
Kitas uždarbis | 2026-08-04 |
|---|
Rinkos kapitalizacija | -22M 1.9B |
|---|---|
Ankstesnė atidarymo kaina | 34.13 |
Ankstesnė uždarymo kaina | 33.6 |
Naujienos nuotaikos
By Acuity
100%
0%
325 / 342 reitingas Healthcare
Harmony Biosciences Holdings Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
